Tailoring the treatment of acute myeloid leukemia

Current Opinion in Hematology

Volumn 6, Issue 4, 1999, Pages 247-252

  Burnett, Alan K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; GROWTH FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW TRANSPLANTATION; CYTARABINE; HUMANS; LEUKEMIA, MYELOID;

EID: 0032778923     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199907000-00009     Document Type: Review

References (29)

1. Rees JKH, Gray RG, Wheatley K: Dose intensification in acute myeloid leukemia: greater effectiveness at lower cost. Principal report of the MRC's AMI 9 Study. Brit J Haem 1996, 94:89-98.
2. Bishop JF, Lowenthal PM, Joshua D, Matthews JP, Todd D, Cobcroft R, et al.: Etoposide in acute non-lymphoblastic leukemia. Blood 1990, 75:27-32.
3. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, et al.: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87:1710-1717.
4. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al.: A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study. Blood 1996, 88:2841-2851.
5. Mayer RJ, Davies RB, Schiffer CA, Beng DT, Powell BL, Schulman P, et al.: Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994, 331:896-903.
6. Elonen E, Almqvist A, Hanninen A, Jansson S-E, Jarventie G, Koistinen P, et al.: Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia 1998, 12:1041-1048. A trial in patients 16 to 65 years of age comparing four and eight cycles of chemotherapy. The overall survival was 36% at five years. There were no significant differences in relapse-free or overall survival between arms.
7. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al.: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995, 332:217-223.
8. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, et al.: Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996, 334:1428-1434.
9. Amadori S, Testi AM, Arico M Camelli A, Giuliano M, Madon E, et al.: Prospective comparative study of bone marrow transplantation and post remission chemotherapy for childhood acute myelogenous leukaemia. J Clin Oncol 1993, 11:1046-1054.
10. Harousseau J-L, Cahn J-Y, Pignon B, Witz F, Milipied N, Delain M, et al.: Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997, 90:2978-2986. A major trial of autologous BMT versus further chemotherapy in CR 1. The study showed a possible reduction in relapse risk but no difference in event-free or overall survival. This is a major study in adults which does not show benefit for the autograft arm.
11. Burnett AK, Goldstone AH, Stevens RMF, Hann IM, Rees JKH, Gray RG, Wheatley K: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 Trial. Lancet 1998, 351:700-708. This is the largest trial evaluating autograft. The design is different from other studies in that all patients received four courses of intensive treatment which resulted in a five-year survival of 40%. Three hundred ninety patients were randomized to receive autograft or no further treatment and there was a very significant reduction in relapse risk and improved disease-free survival, but overall survival did not reach statistical significance. Results are also analyzed by major risk groups.
12. Cassileth P, Harrington E, Paietta E, Lazarus H, Appelbaum F, Blume K, et al.: Comparison of autologous bone marrow transplant (AUTOBMT) with high-dose cytarabine (HDAC) in adult acute myeloid leukemia (AML) in first remission (CR1): an ECOG Intergroup study [abstract]. Proc Am Soc Clin Oncol 1997, 16:89a.
13. Gale RP, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R, et al.: Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995, 16:203-208.
14. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D, et al.: Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study. Blood 1997, 90:2931-2938. A registry study looking at the influence of karyotype in 500 recipients of allografts and 499 autograft recipients. Risk group definition varies with other accepted classifications but confirms that karyotype risk group influences the outcome of transplant.
15. Zittoun R, Suciu S, Watson M, Solbu G, Muus P, Mandelli F, et al.: Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIEMEMA AML 8A trial. Bone Marrow Transplant 1997, 20:307-315. A quality-of-life analysis of 98 patients from the EORTC 8A trial which compared allogeneic BMT versus autologous BMT versus intensive chemotherapy. Not unexpectedly, allogeneic BMT had a greater negative impact than autologous BMT, which in turn was more deleterious than intensive chemotherapy.
16. Mrozek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PRK, Rao KW, et al.: Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: A Cancer and Leukemia Group B study. Blood 1997, 90:4532-4538. This is a study of 24 adults with t(9;11) compared with 23 patients with other 11q23 translocations. The patients with t(9;11) had a better CR rate (79% vs 57%) and superior CR duration, event-free survival, and median survival.
17. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer RJ: Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group [abstract]. Blood 1994, B4(suppl 1):111a.
18. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, et al.: Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997, 90:1643-1648. A comparison of 16 patients with t(8;21) disease which expressed CD56 and those which lacked CD56 expression. CR duration was significantly shorter in those with CD56 expression which resulted in poorer survival.
19. Van Putten WLJ, Lowenberg B: Prognostic factors in adult AML [abstract]. Blood 1997, 90(suppl 1):65a.
20. Fenaux P, LeDely MC, Castaigne S, Archimbaud E, Chomienne C, Link H, et al.: Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a Multicenter Randomized Trial. Blood 1993, 82:3241-3249.
21. Tallman MS, Anderson JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al.: All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337:1021-1028. A prospective trial aimed at defining when ATRA is best used in APL. ATRA included in the schedule at any stage improves results. Reports notably poor outcome in the chemotherapy control arm.
22. Arceci RJ: Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993, 81:2215-2222.
23. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, et al.: Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/Efflux+ and MDR1 +/Efflux-cases. Blood 1995, 86:2329-2342.
24. Archinal-Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itoh Y, Combates NJ, et al.: Analysis of the interactions of SDZ PSC 833 ([3′ - keto-Bmt1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 1995, 7:603-610.
25. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jager U, et al.: Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukaemia. Blood 1998, 91:1508-1513. The second report of the prognostic value of LRP expression. This report only involves 31 positive patients out of 86 studied. The LRP-positive patients had a poor CR and survival. A small number of patients were also analyzed for Pgp co-expression, which provides further prognostic definition.
26. Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, et al.: Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group Randomized Phase III Study AML-9. J Clin Oncol 1998, 16:872-881. A major EORTC trial in older patients showing a trend for better CR rate in the mitoxantrone arm, but no difference in survival. The trial evaluates maintenance with low dose ara-C versus no further treatment. The low-dose ara-C significantly improved disease free survival but not overall survival.
27. Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GEG, Vellenga E, et al.: Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1997, 90:2952-2961.
28. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, et al.: A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031). Blood 1998, 91:3607-3615. This trial adds to the volume of trials of G. or GM-CSF in AML in the older patient.
29. Witz F, Sadoun A, Perrin MC, Berthou C, Briere J, Cahn J-Y, et al.: A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998, 91:2722-2730 This paper presents the result of a GN-CSF trial which does not show survival benefit in older patients but was strikingly beneficial in patients ages 55 to 65 years.